Hong Kong – February 24 2015 – A study comparing DIAMOND therapy with the gold-standard insulin treatment concluded that DIAMOND therapy was a well-tolerated alternative to insulin therapy.
The pilot study examined obese Chinese patients suffering from type 2 diabetes, for whom oral antidiabetes drugs had failed. The investigators compared eight patients who received the DIAMOND therapy with eight patients who received insulin treatment over a period of 12 months. By the end of the period both groups showed improvement in glycemic control with visible reduction on HbA1c levels. However, while body weight, body fat, waist circumference, and blood pressure improved in patients under DIAMOND therapy, all these parameters worsened under insulin treatment.
Dr. Wong, the lead investigator, explained the basis for the study – “Insulin treatment is the gold-standard option for improving blood sugar levels when oral therapy fails. Nevertheless, the price that insulin patients pay is not limited to the disruption of their daily routine. Patients under insulin often gain weight, develop a higher blood pressure and face a higher risk of hospitalization due to a glycemic shock. China is facing the highest toll to this pandemic, and it is up to the leading research institutes to find better solutions for physicians and their patients. The promising results of this study are a part of the growing body of clinical evidence demonstrating the efficacy of DIAMOND therapy and its relevance in the clinical setting.”
Dr. Simon Kin-Hung Wong works at the Departments of Surgery and Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, The Prince of Wales Hospital, Hong Kong Special Administrative Region, China.
Read more about this study here: http://www.ncbi.nlm.nih.gov/pubmed/25710812
About type 2 diabetes
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.
About DIAMOND therapy
DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin. The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections. Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss. DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA. For more information, visit www.MetaCure.com/DIAMOND.
MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device. For more information, visit MetaCure.com.
About Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.